Category Research

SAPPHIRE Trial: Apitegromab Boosts Motor Function in SMA, Published in The Lancet Neurology

Scholar Rock Announces Landmark Lancet Neurology Publication of Pivotal Phase 3 SAPPHIRE Trial Results for Apitegromab in Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to advancing innovative treatments for serious neuromuscular diseases, announced today that…

Read MoreSAPPHIRE Trial: Apitegromab Boosts Motor Function in SMA, Published in The Lancet Neurology

Pilatus, Roche Partner on First-in-Human PLT012 Liver Cancer Trial

Pilatus Biosciences Launches Clinical Trial Collaboration with Roche to Advance First-in-Human Evaluation of PLT012 in Liver Cancer Pilatus Biosciences, Inc., a biotechnology company focused on developing innovative metabolic checkpoint immunotherapies for difficult-to-treat liver and gastrointestinal cancers, announced today a new…

Read MorePilatus, Roche Partner on First-in-Human PLT012 Liver Cancer Trial

Response Pharma Reports Positive Phase 2 Results for RDX-002 in Post-GLP-1 Care

Response Pharmaceuticals Announces Positive Phase 2 Results for RDX-002 in Post-GLP-1 Obesity Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation therapies for weight management and metabolic health, has reported encouraging top-line results from a double-blind, placebo-controlled…

Read MoreResponse Pharma Reports Positive Phase 2 Results for RDX-002 in Post-GLP-1 Care

Bionova Scientific® Launches New Plasmid DNA Facility in Texas to Meet Rising Biopharma Demand

Bionova Scientific® Inaugurates Advanced Plasmid DNA Production Facility in Texas to Support Surging Global Demand for Cell and Gene Therapy Materials Bionova Scientific®, a full-service biologics contract development and manufacturing organization (CDMO) and a wholly owned subsidiary of the global…

Read MoreBionova Scientific® Launches New Plasmid DNA Facility in Texas to Meet Rising Biopharma Demand

Newron Starts Phase III ENIGMA-TRS Trial of Evenamide for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Launches Pivotal Phase III ENIGMA-TRS Program, Randomizing First Patients to Evaluate Evenamide as an Add-On Therapy in Treatment-Resistant Schizophrenia Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company specializing in therapies for diseases affecting the central and…

Read MoreNewron Starts Phase III ENIGMA-TRS Trial of Evenamide for Treatment-Resistant Schizophrenia

NorthStar Medical Technologies Names Jon Coulter as Non-Executive Chairman

NorthStar Medical Technologies Appoints Jon Coulter as Non-Executive Chairman, Marking a Key Step in Leadership Succession for Continued Growth in the Radiopharmaceutical Sector NorthStar Medical Technologies, LLC, a recognized global innovator in the development, production, and commercialization of advanced radiopharmaceuticals…

Read MoreNorthStar Medical Technologies Names Jon Coulter as Non-Executive Chairman

Tahoe Therapeutics Secures $30M to Develop World’s Largest Human Cell AI Training Dataset

Tahoe Therapeutics Secures $30 Million to Build the World’s Largest Dataset for Training AI-Powered Human Cell Models, Aiming to Transform Precision Medicine Tahoe Therapeutics, a biotechnology company at the intersection of artificial intelligence and cellular biology, has announced the successful…

Read MoreTahoe Therapeutics Secures $30M to Develop World’s Largest Human Cell AI Training Dataset

Charles River Associates Broadens Reach with Expansion of Life Sciences Practice

Charles River Associates Expands Life Sciences Practice with Appointment of Two Seasoned Industry Leaders Charles River Associates (NASDAQ: CRAI), a globally recognized leader in economic, financial, and management consulting, has announced a strategic expansion of its Life Sciences Practice with…

Read MoreCharles River Associates Broadens Reach with Expansion of Life Sciences Practice

Roche’s Susvimo Preserves Vision for 5 Years with Twice-Yearly Dosing in nAMD

Roche’s Susvimo Shows Durable Vision Preservation Over Five Years with Twice-Yearly Treatment in Neovascular AMD Roche has released compelling new long-term data highlighting the extended efficacy, safety, and durability of its innovative eye implant therapy, Susvimo® (ranibizumab injection), for individuals…

Read MoreRoche’s Susvimo Preserves Vision for 5 Years with Twice-Yearly Dosing in nAMD

Altasciences and VoxCell Partner to Boost Preclinical Drug Development

Altasciences and VoxCell BioInnovation Forge Strategic Partnership to Revolutionize Preclinical Drug Development with 3D Bioprinted Human Tissue Models In a move poised to reshape the landscape of early-stage drug development, Altasciences, a fully integrated drug development solution provider, and VoxCell…

Read MoreAltasciences and VoxCell Partner to Boost Preclinical Drug Development